

DAFTAR PUSTAKA

- Baba, M., Inoue, M., Itoh, K., & Nishizawa, Y. (2008). Blocking CD147 induces cell death in cancer cells through impairment of glycolytic energy metabolism. *Biochem Biophys Res Commun*, 374(1), 111-116. doi:10.1016/j.bbrc.2008.06.122
- Bhattacharyya A, D. R., Darwani R. (2010). Giant Cell Tumor of the Talus: A case report and review of literature *The Foot and Ankle Online Journal*, 3. doi:doi: 10.3827/faoj.2010.0308.0002
- Brodbeck, W. G., & Anderson, J. M. (2009). Giant cell formation and function. *Curr Opin Hematol*, 16(1), 53-57. doi:10.1097/MOH.0b013e32831ac52e
- Brooks, P. J., Glogauer, M., & McCulloch, C. A. (2019). An Overview of the Derivation and Function of Multinucleated Giant Cells and Their Role in Pathologic Processes. *Am J Pathol*, 189(6), 1145-1158. doi:10.1016/j.ajpath.2019.02.006
- Chen et all.(2014). Identification of differentially expressed genes and their subpathways in recurrent versus primary bone giant cell tumors. China
- Cheng, D. D., Hu, T., Zhang, H. Z., Huang, J., & Yang, Q. C. (2015). Factors Affecting the Recurrence of Giant Cell Tumor of Bone After Surgery: A Clinicopathological Study of 80 Cases from a Single Center. *Cell Physiol Biochem*, 36(5), 1961-1970. doi:10.1159/000430164
- Conti, A., Rodriguez, G. C., Chiechi, A., Blazquez, R. M., Barbado, V., Krenacs, T., . . . Benassi, M. S. (2011). Identification of potential biomarkers for giant cell tumor of bone using comparative proteomics analysis. *Am J Pathol*, 178(1), 88-97. doi:10.1016/j.ajpath.2010.11.035
- D.M. Fletcher, J. A. B., Pancras C.W. Hogendoorn, Fredrik Mertens. (2013). *WHO Classification of Tumours of Soft Tissue and Bone* (4 ed.). France: International Agency for Research on Cancer.
- Fan, H., Yi, W., Wang, C., & Wang, J. (2017). The clinicopathological significance and prognostic value of EMMPRIN overexpression in cancers: evidence from 39 cohort studies. *Oncotarget*, 8(47), 82643-82660. doi:10.18632/oncotarget.19740
- Grass, G. D., & Toole, B. P. (2015). How, with whom and when: an overview of CD147-mediated regulatory networks influencing matrix metalloproteinase activity. *Biosci Rep*, 36(1), e00283. doi:10.1042/bsr20150256
- Han, Y. H., Gao, B., Huang, J. H., Wang, Z., Guo, Z., Jie, Q., . . . Luo, Z. J. (2015). Expression of CD147, PCNA, VEGF, MMPs and their clinical significance in the giant cell tumor of bones. *Int J Clin Exp Pathol*, 8(7), 8446-8452.

- Haque, A. U., & Moatasim, A. (2008). Giant cell tumor of bone: a neoplasm or a reactive condition? *Int J Clin Exp Pathol*, 1(6), 489-501.
- Hu, X., Su, J., Zhou, Y., Xie, X., Peng, C., Yuan, Z., & Chen, X. (2017). Repressing CD147 is a novel therapeutic strategy for malignant melanoma. *Oncotarget*, 8(15), 25806-25813. doi:10.18632/oncotarget.15709
- Kanekura, T., & Chen, X. (2010). CD147/basigin promotes progression of malignant melanoma and other cancers. *J Dermatol Sci*, 57(3), 149-154. doi:10.1016/j.jdermsci.2009.12.008
- Khayati, F., Perez-Cano, L., Maouche, K., Sadoux, A., Boutalbi, Z., Podgorniak, M. P., . . . Mourah, S. (2015). EMMPRIN/CD147 is a novel coreceptor of VEGFR-2 mediating its activation by VEGF. *Oncotarget*, 6(12), 9766-9780. doi:10.18632/oncotarget.2870
- Kim, Y., Nizami, S., Goto, H., & Lee, F. Y. (2012). Modern interpretation of giant cell tumor of bone: predominantly osteoclastogenic stromal tumor. *Clin Orthop Surg*, 4(2), 107-116. doi:10.4055/cios.2012.4.2.107
- Klenke, F. M., Wenger, D. E., Inwards, C. Y., Rose, P. S., & Sim, F. H. (2011). Giant cell tumor of bone: risk factors for recurrence. *Clin Orthop Relat Res*, 469(2), 591-599. doi:10.1007/s11999-010-1501-7
- Kumar V., A. A., Aster JC (2015). *Robbins and Cotran Pathologic Basis of Disease* (9 ed.). Philadelphia: Elsevier Saunders.
- Landras, A., Reger de Moura, C., Jouenne, F., Lebbe, C., Menashi, S., & Mourah, S. (2019). CD147 Is a Promising Target of Tumor Progression and a Prognostic Biomarker. *Cancers (Basel)*, 11(11). doi:10.3390/cancers11111803
- Lin, F., Hu, Y., Zhao, L., Zhang, H., Yu, X., Wang, Z., ... Wang, J. . (2016). The epidemiological and clinical features of primary giant cell tumor around the knee: A report from the multicenter retrospective study in china. . *Journal of bone oncology*, 5(1), 38–42. doi:doi:10.1016/j.jbo.2016.02.001
- Lu, Q., Lv, G., Kim, A., Ha, J. M., & Kim, S. (2013). Expression and clinical significance of extracellular matrix metalloproteinase inducer, EMMPRIN/CD147, in human osteosarcoma. *Oncol Lett*, 5(1), 201-207. doi:10.3892/ol.2012.981
- Lujic, N., Sopta, J., Kovacevic, R., Stevanovic, V., & Davidovic, R. (2016). Recurrence of giant cell tumour of bone: role of p53, cyclin D1, beta-catenin and Ki67. *Int Orthop*, 40(11), 2393-2399. doi:10.1007/s00264-016-3292-2
- Mescher, A. L. (2011). *Histologi Dasar Junqueira* (F. Dany, Trans. H. Hartanto Ed. 12 ed.). Jakarta: EGC.
- Muramatsu, T. (2016). Basigin (CD147), a multifunctional transmembrane glycoprotein with various binding partners. *J Biochem*, 159(5), 481-490. doi:10.1093/jb/mvv127

- Noh, B. J., & Park, Y. K. (2018). Giant cell tumor of bone: updated molecular pathogenesis and tumor biology. *Hum Pathol*, 81, 1-8. doi:10.1016/j.humpath.2018.06.017
- Qiao, S., Liu, C., Xu, W., AZhaTi, W., Li, C., & Wang, Z. (2018). . = Revista brasileira de pesquisas medicas e biologicas, 51(9), e6948. (2018). Up-regulated expression of CD147 gene in malignant bone tumor and the possible induction mechanism during osteoclast formation. *Brazilian journal of medical and biological research*, 51, 1-8. doi: doi:10.1590/1414-431X20186948
- Qu, X., Wang, C., Zhang, J., Qie, G., & Zhou, J. (2014). The roles of CD147 and/or cyclophilin A in kidney diseases. *Mediators Inflamm*, 2014, 728673. doi:10.1155/2014/728673
- Rao, U. N., Goodman, M., Chung, W. W., Swalski, P., Pal, R., & Finkelstein, S. (2005). Molecular analysis of primary and recurrent giant cell tumors of bone. *Cancer Genet Cytogenet*, 158(2), 126-136. doi:10.1016/j.cancergencyto.2004.09.015
- Riethdorf, S., Reimers, N., Assmann, V., Kornfeld, J. W., Terracciano, L., Sauter, G., & Pantel, K. (2006). High incidence of EMMPRIN expression in human tumors. *Int J Cancer*, 119(8), 1800-1810. doi:10.1002/ijc.22062
- Si, A. I., Huang, L., Xu, J., Kumta, S. M., Wood, D., & Zheng, M. H. (2003). Expression and localization of extracellular matrix metalloproteinase inducer in giant cell tumor of bone. *J Cell Biochem*, 89(6), 1154-1163. doi:10.1002/jcb.10578
- Siddiqui, M. A., Seng, C., & Tan, M. H. (2014). Risk factors for recurrence of giant cell tumours of bone. *J Orthop Surg (Hong Kong)*, 22(1), 108-110. doi:10.1177/230949901402200127
- Singh, A. S., Chawla, N. S., & Chawla, S. P. . (2015). Giant-cell tumor of bone: treatment options and role of denosumab. *Biologics : targets & therapy*, 9, 69–74. doi:doi:10.2147/BTT.S57359
- Sun, J., & Hemler, M. E. (2001). Regulation of MMP-1 and MMP-2 production through CD147/extracellular matrix metalloproteinase inducer interactions. *Cancer Res*, 61(5), 2276-2281.
- Takeuchi, A., Tsuchiya, H., Niu, X., Ueda, T., Jeon, D. G., Wang, E. H., . . . Kang, Y. K. (2011). The prognostic factors of recurrent GCT: a cooperative study by the Eastern Asian Musculoskeletal Oncology Group. *J Orthop Sci*, 16(2), 196-202. doi:10.1007/s00776-011-0030-x
- Tang, Y., Nakada, M. T., Rafferty, P., Laraio, J., McCabe, F. L., Millar, H., . . . Yan, L. (2006). Regulation of vascular endothelial growth factor expression by EMMPRIN via the PI3K-Akt signaling pathway. *Mol Cancer Res*, 4(6), 371-377. doi:10.1158/1541-7786.Mcr-06-0042
- Thompson, J. C. (2010). *Netter's Concise Orthopaedic Anatomy Second Edition* (O. G. E Ed. Second ed.). Philadelphia: Elsevier.
- Ulviye yalcinkaya et All. (2015) prognostic value Of p53 protein expression in giant cell tumor Of bone. turkey

- Wang Z, Z. Z., Jiang T. (2016). The Multistep Functions of EMMPRIN/CD147 in the Tumor Angiogenesis. *Cell Mol Med*, 2, 1-5. doi:10.21767/2573-5365.100012
- Weidle, U. H., Scheuer, W., Eggle, D., Klostermann, S., & Stockinger, H. (2010). Cancer-related issues of CD147. *Cancer Genomics Proteomics*, 7(3), 157-169.
- Werner, M. (2006). Giant cell tumour of bone: morphological, biological and histogenetical aspects. *Int Orthop*, 30(6), 484-489. doi:10.1007/s00264-006-0215-7
- Xin, X., Zeng, X., Gu, H., Li, M., Tan, H., Jin, Z., . . . Wang, H. (2016). CD147/EMMPRIN overexpression and prognosis in cancer: A systematic review and meta-analysis. *Sci Rep*, 6, 32804. doi:10.1038/srep32804
- Xiong, L., Edwards, C. K., 3rd, & Zhou, L. (2014). The biological function and clinical utilization of CD147 in human diseases: a review of the current scientific literature. *Int J Mol Sci*, 15(10), 17411-17441. doi:10.3390/ijms151017411
- Yan, L., Zucker, S., & Toole, B. P. (2005). Roles of the multifunctional glycoprotein, emmprin (basigin; CD147), in tumour progression. *Thromb Haemost*, 93(2), 199-204. doi:10.1160/th04-08-0536
- Zheng, M. H., Robbins, P., Xu, J., Huang, L., Wood, D. J., & Papadimitriou, J. M. (2001). The histogenesis of giant cell tumour of bone: a model of interaction between neoplastic cells and osteoclasts. *Histol Histopathol*, 16(1), 297-307. doi:10.14670/hh-16.297
- Zhong, W. D., Liang, Y. X., Lin, S. X., Li, L., He, H. C., Bi, X. C., . . . Wu, C. L. (2012). Expression of CD147 is associated with prostate cancer progression. *Int J Cancer*, 130(2), 300-308. doi:10.1002/ijc.25982